NCT06112314Phase 3Listed as recruiting
Advanced melanoma, not treated before: a new immunotherapy compared with nivolumab
This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.
Minimum age: 18 years
Centres in: Cluj-Napoca · Craiova · Iași
See all centres (3)Hide the centre list
These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.
Central study contact
To find the team and exact institution in your chosen city, quote study NCT06112314. This contact may be in another country; ask which language you can use.
Immunocore Medical Information
844-466-8661 (dialling format unconfirmed)
Immunocore Medical Information EU
+00 800-744-51111 (dialling format unconfirmed)
Source: study registry
Cluj-Napoca
L'Institute Oncologique Prof. Dr. Ion Chiricuta (IOCN) (The Oncology Institute Prof. Dr. Ion. Chiricuta)
Craiova
Sf Nectarie Oncology Center
Contact for this study
Source: study registry
Iași
Victoria Hospital (Centrul de oncologie Euroclinic SRL) (Centrul De Oncologie Medicala) (Euroclinic Onchology Center)
Who can take part
Advanced melanoma, not treated before: a new immunotherapy compared with nivolumab
This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanced melanoma.
- Minimum age:
- 18 years
- Maximum age:
- Not specified in the record consulted
- Participant sex, as recorded in the registry:
- All sexes
This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.
Criteria published in the registry — English original
Inclusion Criteria: * Participants must be HLA-A\*02:01-positive * Participants must have histologically confirmed Stage IV or unresectable Stage III melanoma * Archived or fresh tumor tissue sample that must be confirmed as adequate * Participants must have measurable disease per RECIST 1.1 * Participant must have BRAF V600 mutation status determined * Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 * Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control from the study screening date until 5 months after the final dose of study intervention Exclusion Criteria: * Participants with a history of a malignant disease other than those being treated in this study * Participants with untreated, active, or symptomatic central nervous system (CNS) metastases or carcinomatous meningitis * Hypersensitivity to IMC-F106C, nivolumab, relatlimab, or any associated excipients * Participants with clinically significant pulmonary disease or impaired lung function * Participants with clinically significant cardiac disease or impaired cardiac function * Participants with active autoimmune disease requiring immunosuppressive treatment * Participants with any medical condition that is poorly controlled or that would, in the Investigator's or Sponsor's judgment, adversely impact the participant's participation in the clinical study due to safety concerns, compliance with clinical study procedures, or interpretation of study results * Participants who received prior systemic anticancer therapy for unresectable or metastatic melanoma * Participants with a history of a life-threatening AE related to prior anti-PD-(L)1 or anti-LAG-3
What taking part involves
Participants are randomly assigned to the study groups.
These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.
Group 1 · Studied intervention
Brenetafusp · Nivolumab
Group 2 · Studied intervention
Brenetafusp · Nivolumab
Group 3 · Active treatment comparison
Nivolumab · Nivolumab + Relatlimab
- Start of the whole study
- 5 June 2024
- Completion of the whole study
- 16 October 2027 (estimated)
These are global study dates, not an individual's participation duration or an enrolment deadline.
Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.
Ask the study team before travelling:
- whether places are available at the chosen centre and how the first assessment is arranged
- how often you need to attend the centre and whether a hospital stay is necessary
- whether travel or accommodation costs are covered and under what conditions
- which documents you need to prepare and whether a family member or carer can accompany you
Original registry title
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Updated in the registry: 25 February 2026
Data consulted: 19 November 2026
See the official record ↗If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.
